Compare JAGU & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAGU | LITS |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | Canada | United States |
| Employees | 3 | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 44.4M |
| IPO Year | N/A | N/A |
| Metric | JAGU | LITS |
|---|---|---|
| Price | $2.47 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 170.0K | ★ 281.4K |
| Earning Date | 03-27-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $0.95 |
| 52 Week High | $3.60 | $3.03 |
| Indicator | JAGU | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 60.41 |
| Support Level | $2.21 | $1.13 |
| Resistance Level | $2.60 | $1.25 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 22.64 | 88.82 |
Jaguar Uranium Corp is a uranium exploration and development company focused on uranium discoveries. The company is a junior miner engaged in uranium exploration. Its portfolio is comprised of two uranium exploration projects in Argentina and one uranium exploration project in Colombia. Its projects include the Berlin Project, the Laguna Project, and the Huemul Project. The company operates in one reportable segment which is the exploration and evaluation of mineral properties.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.